20,000 Shares in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Purchased by Drive Wealth Management LLC

Drive Wealth Management LLC bought a new position in shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm bought 20,000 shares of the company’s stock, valued at approximately $36,000. Drive Wealth Management LLC owned approximately 0.06% of Reviva Pharmaceuticals as of its most recent SEC filing.

Separately, Geode Capital Management LLC increased its position in shares of Reviva Pharmaceuticals by 17.9% during the 3rd quarter. Geode Capital Management LLC now owns 278,496 shares of the company’s stock worth $401,000 after purchasing an additional 42,376 shares in the last quarter. 63.18% of the stock is currently owned by hedge funds and other institutional investors.

Reviva Pharmaceuticals Price Performance

Shares of NASDAQ:RVPH opened at $1.77 on Wednesday. Reviva Pharmaceuticals Holdings, Inc. has a one year low of $0.60 and a one year high of $4.83. The company has a 50 day moving average of $1.73 and a 200-day moving average of $1.34. The stock has a market cap of $59.19 million, a price-to-earnings ratio of -1.59 and a beta of -0.12.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the stock. HC Wainwright dropped their target price on shares of Reviva Pharmaceuticals from $14.00 to $11.00 and set a “buy” rating for the company in a research report on Wednesday, January 22nd. D. Boral Capital restated a “buy” rating and issued a $15.00 price objective on shares of Reviva Pharmaceuticals in a research report on Tuesday, January 21st. Maxim Group upgraded shares of Reviva Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 price objective for the company in a research report on Friday, January 10th. Roth Capital upgraded shares of Reviva Pharmaceuticals to a “strong-buy” rating in a research report on Friday, January 10th. Finally, Roth Mkm started coverage on shares of Reviva Pharmaceuticals in a research report on Friday, January 10th. They issued a “buy” rating and a $7.00 price objective for the company. Five analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $11.40.

Reviva Pharmaceuticals Profile

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.